MedTrace Logo

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

NCT00466687 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2013-07-22

Study results available
· View outcomes & findings →

Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage IV melanoma.

Conditions

Interventions

BIOLOGICAL

bevacizumab

10mg/kg, slow IV infusion, Days 1 and 14

DRUG

erlotinib hydrochloride

150mg PO qd

GENETIC

fluorescence in situ hybridization

Targeting multiple genetic aberrations in isolated tumor cells.

GENETIC

gene expression analysis

gene expression analysis

OTHER

immunologic technique

immunologic technique

OTHER

laboratory biomarker analysis

laboratory biomarker analysis

PROCEDURE

biopsy

biopsy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Jeffrey A. Sosman, MD · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2008-08-31
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00466687 on ClinicalTrials.gov